Jeffrey Melson Clarke Selected Research

ascrinvacumab

10/2019

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey Melson Clarke Research Topics

Disease

1	Colorectal Neoplasms (Colorectal Cancer) 10/2019
1	Insulin Resistance 01/2019
1	Neoplasms (Cancer) 01/2019
1	Hyperglycemia 01/2019
1	Stomach Neoplasms (Stomach Cancer) 08/2013

Drug/Important Bio-Agent (IBA)

1	regorafenibIBA 10/2019
1	Monoclonal AntibodiesIBA 10/2019
1	Activin Receptors (Activin Receptor)IBA 10/2019
1	ascrinvacumabIBA 10/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	RamucirumabIBA 08/2013

Therapy/Procedure

1	Therapeutics 01/2019
1	Precision Medicine 01/2019
1	Immunotherapy 01/2019